Complete Mobile Drug Testing
Source filing: WI · filed 2026-06-06
Item 5 — Initial franchise fee
$40,000 [p.11 · WI · 2026-06-06]
Item 6 — Recurring fees (royalty & advertising)
| Royalty | See FDD [p.11 · WI · 2026-06-06] |
|---|---|
| Marketing Fund Contribution | See FDD [p.11 · WI · 2026-06-06] |
Full Item 6 schedule (including one-time and conditional fees) is in the FDD itself.
Item 7 — Estimated initial investment (total)
$67,850 [p.17 · WI · 2026-06-06] – $287,650 [p.17 · WI · 2026-06-06]
Base single-franchise offering as stated in the FDD's total row. Multi-unit or area-development formats are not broken out here.
Item 20 — Outlets
| Franchised outlets at start of year | 0 [p.39 · WI · 2026-06-06] |
|---|---|
| Franchised outlets at end of year | 0 [p.39 · WI · 2026-06-06] |
| Net change in franchised outlets | 0 [p.39 · WI · 2026-06-06] |
| Transfers | Not disclosed |
| Terminations | Not disclosed |
| Non-renewals | Not disclosed |
| Ceased operations (other) | Not disclosed |
| Company-owned outlets at end of year | 1 [p.39 · WI · 2026-06-06] |
Item 19 — Financial performance representation
The filing's Item 19 contains no cohort eligible for headline presentation under this site's rules (franchised population, gross revenue/sales, annual, not a ranked subset).
All disclosed cohorts (1)
| Cohort | Outlets | Average | Median | High | Low |
|---|---|---|---|---|---|
| affiliate-owned outlet (Complete Mobile Drug Testing, LLC) calendar year 2025, equivalent of approximately 6 territories 2025 excluded: failed consistency checks |
Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed |
“The table above shows a summary adjusted profit statement for the Complete Mobile Drug Testing operated by our affiliate, Complete Mobile Drug Testing, LLC, in calendar year 2025.” [p.38 · WI · 2026-06-06]
Extraction notes
- Item 7 totals were extracted with model assistance and verified against the cited page.